Table 2

Colonic tissue concentrations of endogenous TFF2 and TFF3 (experiment 1)

Group no.TreatmentnTFF2 (pmol/mg protein)TFF3 (pmol/mg protein)
11% DSS32.13 ± 0.24a,b105.0 ± 33.3
21% DSS/troglitazone (10 mg/kg bw i.g.)31.60 ± 0.14102.7 ± 35.6
31% DSS/troglitazone (100 mg/kg bw i.g.)30.92 ± 0.15c94.0 ± 31.1
41% DSS/bezafibrate (10 mg/kg bw i.g.)31.66 ± 0.16100.3 ± 31.3
51% DSS/bezafibrate (100 mg/kg bw i.g.)31.01 ± 0.1897.9 ± 23.7
6Troglitazone (100 mg/kg bw i.g.)30.68 ± 0.0859.3 ± 13.3
7Bezafibrate (100 mg/kg bw i.g.)30.71 ± 0.0758.4 ± 6.7
8None30.67 ± 0.0756.0 ± 8.9
  • a Mean ± SD. bw, body weight; i.g., intragastrically.

  • b Significantly different from group 8 (P < 0.02).

  • c Significantly different from group 1 (P < 0.05).